TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06980948: Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)

Sponsor: Sangamo Therapeutics · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 27 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,451,120

Rescue Site Savings

+$956,420

Unlock Full NCT06980948 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06980948 Rescue Dossier →